Whitehawk Therapeutics unveils ADC pipeline and preclinical data in new corporate presentation

Reuters11-18

Whitehawk <a href="https://laohu8.com/S/LENZ">Therapeutics</a> unveils ADC pipeline and preclinical data in new corporate presentation

Whitehawk Therapeutics Inc. has released a corporate presentation detailing its advancements in antibody-drug conjugate $(ADC)$ technology. The company's pipeline features three ADC assets, including HWK-007 targeting PTK7 and HWK-016 targeting MUC16, both expected to enter Phase 1 clinical trials with indications across several cancer types such as non-small cell lung, ovarian, endometrial, and mesothelioma. The presentation highlights the novel linker-payload technology utilized in Whitehawk's ADC platform, which is designed for enhanced potency, stability, and safety compared to average topoisomerase I inhibitor ADCs. Preclinical data show greater tumor potency, improved stability in circulation, and a higher safety margin in animal models. As of September 30, 2025, Whitehawk reported $162.6 million in cash, with an anticipated runway into 2028. Key investors include Kalehua and Ally Bridge Group. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584931441?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584931441","market":"fut","top_or_hot":-1,"title":"Whitehawk Therapeutics unveils ADC pipeline and preclinical data in new corporate presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Whitehawk <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> unveils ADC pipeline and preclinical data in new corporate presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Whitehawk Therapeutics Inc. has released a corporate presentation detailing its advancements in antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> technology. The company's pipeline features three ADC assets, including HWK-007 targeting PTK7 and HWK-016 targeting MUC16, both expected to enter Phase 1 clinical trials with indications across several cancer types such as non-small cell lung, ovarian, endometrial, and mesothelioma. The presentation highlights the novel linker-payload technology utilized in Whitehawk's ADC platform, which is designed for enhanced potency, stability, and safety compared to average topoisomerase I inhibitor ADCs. Preclinical data show greater tumor potency, improved stability in circulation, and a higher safety margin in animal models. As of September 30, 2025, Whitehawk reported $162.6 million in cash, with an anticipated runway into 2028. Key investors include Kalehua and Ally Bridge Group. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Whitehawk Therapeutics unveils ADC pipeline and preclinical data in new corporate presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhitehawk Therapeutics unveils ADC pipeline and preclinical data in new corporate presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Whitehawk <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> unveils ADC pipeline and preclinical data in new corporate presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Whitehawk Therapeutics Inc. has released a corporate presentation detailing its advancements in antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> technology. The company's pipeline features three ADC assets, including HWK-007 targeting PTK7 and HWK-016 targeting MUC16, both expected to enter Phase 1 clinical trials with indications across several cancer types such as non-small cell lung, ovarian, endometrial, and mesothelioma. The presentation highlights the novel linker-payload technology utilized in Whitehawk's ADC platform, which is designed for enhanced potency, stability, and safety compared to average topoisomerase I inhibitor ADCs. Preclinical data show greater tumor potency, improved stability in circulation, and a higher safety margin in animal models. As of September 30, 2025, Whitehawk reported $162.6 million in cash, with an anticipated runway into 2028. Key investors include Kalehua and Ally Bridge Group. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WHWK","symbol_name":"Whitehawk Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL84wPLZ:1","article_id":"2584931441","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584931441","pubTimestamp":1763466078,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Whitehawk Therapeutics Inc. has released a corporate presentation detailing its advancements in antibody-drug conjugate  technology. The company's pipeline features three ADC assets, including HWK-007 targeting PTK7 and HWK-016 targeting MUC16, both expected to enter Phase 1 clinical trials with indications across several cancer types such as non-small cell lung, ovarian, endometrial, and mesothelioma. The presentation highlights the novel linker-payload technology utilized in Whitehawk's ADC platform, which is designed for enhanced potency, stability, and safety compared to average topoisomerase I inhibitor ADCs. Preclinical data show greater tumor potency, improved stability in circulation, and a higher safety margin in animal models. As of September 30, 2025, Whitehawk reported $162.6 million in cash, with an anticipated runway into 2028. Key investors include Kalehua and Ally Bridge Group. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WHWK":"Whitehawk Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Whitehawk Therapeutics在新的公司演示中公布了ADC管道和临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WHWK":0.9},"content_text":"Whitehawk Therapeutics unveils ADC pipeline and preclinical data in new corporate presentation\n    \n\n        Whitehawk Therapeutics Inc. has released a corporate presentation detailing its advancements in antibody-drug conjugate $(ADC)$ technology. The company's pipeline features three ADC assets, including HWK-007 targeting PTK7 and HWK-016 targeting MUC16, both expected to enter Phase 1 clinical trials with indications across several cancer types such as non-small cell lung, ovarian, endometrial, and mesothelioma. The presentation highlights the novel linker-payload technology utilized in Whitehawk's ADC platform, which is designed for enhanced potency, stability, and safety compared to average topoisomerase I inhibitor ADCs. Preclinical data show greater tumor potency, improved stability in circulation, and a higher safety margin in animal models. As of September 30, 2025, Whitehawk reported $162.6 million in cash, with an anticipated runway into 2028. Key investors include Kalehua and Ally Bridge Group. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584931441","isCrawlerRequest":true}